Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 14/20 | 0.82 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.49 |
| ▸ | PRKDC | P78527 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | GCK | P35557 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609805 | 0.90 | PIK3CG (1.00) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10086060 | 0.89 | PIK3CG (0.77) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085340 | 0.88 | PIK3CG (0.78) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085350 | 0.84 | PIK3CG (0.75) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085345 | 0.81 | PIK3CG (0.76) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085342 | 0.79 | PIK3CG (0.63) | PIK3CGPIK3CDNTRK1PRKDCGCK | |
| SCHEMBL609523 | 0.78 | PIK3CG (1.00) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085375 | 0.77 | PIK3CD (0.80) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085399 | 0.77 | PIK3CG (0.75) | PIK3CGPIK3CDNTRK1PRKDCJAK2 | |
| SCHEMBL10085714 | 0.76 | PIK3CG (0.73) | PIK3CGPIK3CDNTRK1PRKDCJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524906-B2 | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120039849-A1 | TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CA, PIK3CD, PIK3CG | PIK3CG 3/4885PIK3CD 2/4885NTRK1 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.